| Current Price | $73.30 | Mkt Cap | $7.7B |
|---|---|---|---|
| Open | $69.35 | P/E Ratio | 0.00 |
| Prev. Close | $73.30 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $69.05 - $73.31 | Volume | 428,193 |
| 52-Wk Range | $56.39 - $195.78 | Avg. Daily Vol. | 781,759 |
| Current Price | $73.30 | Mkt Cap | $7.7B |
|---|---|---|---|
| Open | $69.35 | P/E Ratio | 0.00 |
| Prev. Close | $73.30 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $69.05 - $73.31 | Volume | 428,193 |
| 52-Wk Range | $56.39 - $195.78 | Avg. Daily Vol. | 781,759 |
The best Bull and Bear pitches based on recency and number of recommendations.
Read the most recent pitches from players about NVCR.
Recs
Foolme21
(< 20)
Submitted: 3/10/2022 12:20:15 PM :
Start Price:
$64.66
NASDAQ:NVCR Score:
+21.58
TTFields have extended overall patient survival for glioblastoma (GBM). Based on successful GBM treatment and research indicating that TTFields can improve treatment for other cancers, Novocure's TAM will greatly expand. Results from the LUNAR (non-small cell lung cancer, NSCLC) and INNOVATE-3 (ovarian cancer) phase 3 clinical trials are due later in 2022/2023, respectively. If trials indicate TTFields extend patient survival beyond GBM, then NovoCure will outperform the S&P 500.
Recs
Reserved1
(< 20)
Submitted: 1/7/2022 10:18:28 AM :
Start Price:
$68.92
NASDAQ:NVCR Score:
+23.89
Medical research with little to no competition
Recs
willieram
(< 20)
Submitted: 11/22/2021 1:07:53 PM :
Start Price:
$97.69
NASDAQ:NVCR Score:
-6.60
Fourth method for cancer treatment. Non invasive technology, no side effects, potentially able to treat most tumors. Revolutionary.
Find the members with the highest scoring picks in NVCR.
oldlumike (37.81) Score: +529.29
The Score Leader is the player with the highest score across all their picks in NVCR.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
|
stcksrus | 74.54 |
|
|
5Y | $11.69 | +521.98% | +75.57% | +446.41 | 0 Comment |
| synapse | 66.49 | 10/20/2017 |
|
5Y | $18.25 | +298.41% | +48.55% | +249.86 | 0 Comment | |
| findil | 53.05 | 10/23/2017 |
|
5Y | $18.43 | +294.63% | +48.29% | +246.34 | 1 Comment | |
| SuzyP99 | 74.05 | 8/23/2017 |
|
1Y | $18.75 | +287.79% | +56.07% | +231.72 | 1 Comment | |
|
|
skyrocket29 | 65.27 | 8/22/2017 |
|
1Y | $19.10 | +280.68% | +56.55% | +224.13 | 0 Comment |
| tprooney3 | 94.51 | 7/17/2017 |
|
5Y | $19.25 | +277.71% | +55.34% | +222.37 | 1 Comment | |
| XMFpessen | 43.23 | 12/5/2017 |
|
5Y | $19.95 | +264.55% | +44.30% | +220.26 | 0 Comment | |
| only1ferret | 50.10 | 12/6/2017 |
|
5Y | $20.08 | +262.19% | +44.67% | +217.52 | 0 Comment | |
|
|
ATrain | 36.35 | 12/21/2017 |
|
5Y | $20.25 | +259.06% | +42.42% | +216.64 | 0 Comment |
| TMFTypeoh | 91.88 | 4/3/2018 |
|
5Y | $20.05 | +262.64% | +47.43% | +215.21 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
